Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Treasury Shares (2016 - 2025)

Historic Treasury Shares for Editas Medicine (EDIT) over the last 11 years, with Q3 2025 value amounting to $652267.0.

  • Editas Medicine's Treasury Shares fell 7432.48% to $652267.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $652267.0, marking a year-over-year decrease of 7432.48%. This contributed to the annual value of $2.3 million for FY2024, which is 1041.1% up from last year.
  • Editas Medicine's Treasury Shares amounted to $652267.0 in Q3 2025, which was down 7432.48% from $923539.0 recorded in Q2 2025.
  • In the past 5 years, Editas Medicine's Treasury Shares ranged from a high of $2.7 million in Q1 2024 and a low of $628732.0 during Q4 2021
  • Moreover, its 5-year median value for Treasury Shares was $1.5 million (2025), whereas its average is $1.6 million.
  • Its Treasury Shares has fluctuated over the past 5 years, first surged by 13842.75% in 2022, then plummeted by 7432.48% in 2025.
  • Editas Medicine's Treasury Shares (Quarter) stood at $628732.0 in 2021, then skyrocketed by 138.43% to $1.5 million in 2022, then skyrocketed by 40.56% to $2.1 million in 2023, then rose by 10.41% to $2.3 million in 2024, then crashed by 71.96% to $652267.0 in 2025.
  • Its Treasury Shares was $652267.0 in Q3 2025, compared to $923539.0 in Q2 2025 and $1.5 million in Q1 2025.